FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PICKERING GRANT	Requiring S (Month/Day	2. Date of Event Requiring Statement (Month/Day/Year) 01/27/2022  3. Issuer Name and Ticker or Trading Symbol Athira Pharma, Inc. [ ATHA ]					
(Last) (First) (Middle) C/O ATHIRA PHARMA, INC.			4. Relationship of Reporting Issuer (Check all applicable)	Person(s) to 10% Owner Other (specif below)	Filed	If Amendment, Date of Original ed (Month/Day/Year)	
18706 NORTH CREEK PARKWAY, SUITE 104	_		X Director Officer (give title below)		6	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person	
(Street) BOTHELL WA 98011	_						
(City) (State) (Zip)							
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)			2. Amount of Securities	3. Owne	irect Ownership (Instr. 5)		
			Beneficially Owned (Instr. 4)	Form: D (D) or In (I) (Instr	direct	nersnip (instr. :	5)
No securities are beneficially owned.				(D) or In	direct . 5)	nersnip (instr. :	5)
,		Derivative	4)	(D) or in (I) (Instr	ed	nersnip (instr. :	5)
,		Derivative Ils, warran	0 e Securities Beneficial	(D) or In (I) (Instruction (I) (Instruction (I) (Instruction (I) (Instruction (I)	ed urities)	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr.
(e.ç	., puts, cal  2. Date Exerc Expiration Da	Derivative Ils, warran	0 e Securities Beneficial nts, options, convertil 3. Title and Amount of Sec Underlying Derivative Sec (Instr. 4)	(D) or In (I) (Instruction (I) (Instruction (I) (Instruction (I) (Instruction (I)	ed urities) 4. Conversio	5. 1 Ownership	6. Nature of Indirect Beneficial

#### Explanation of Responses:

1. Not applicable.

#### Remarks:

Glenna Mileson, Attorneyin-fact for Grant Pickering 01/31/2022

\*\* Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Athira Pharma, Inc. (the Company), hereby constitutes and appoints Glenna Mileson, Vieng Keophilavanh and each of the responsible attorneys and paralegals of Wilson Sonsini Goodrich & Rosati, Professional Corporation, the true and lawful attorney-in-fact of the undersigned to:

- 1. complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and
- 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the

holdings of and transactions in securities issued by the Company to the undersigned, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 19, 2022.

Signature: /s/ Grant Pickering